eClinical Technology and Industy News

Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

WARRINGTON, Pa., Jan. 6, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Lucinactant is the Company’s synthetic KL4 surfactant that is structurally similar to human pulmonary surfactant.

“With COVID-19 cases continuing to increase across the U.S. and globally there’s considerable need to develop effective new treatments for those who develop respiratory failure, particularly therapies that can help reduce the intensity of care in the hospital where the availability of beds, ventilators and ICU space are fast reaching short supply levels,” said Steve Simonson, M.D., chief medical officer at Windtree Therapeutics. “We have built a strong body of preclinical evidence supporting the potential use of KL4 surfactant for acute lung injury caused by multiple insults including viral infection and we believe that surfactant therapy could potentially play an important role in supporting COVID-19 patients who develop severe respiratory disease.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives